Meet Avalere Health Experts at ISPOR

This is a great opportunity to connect face-to-face with an expert specialist in Health Economics and Outcomes Research (HEOR)/real-world evidence (RWE), evidence and strategy, market access, or policy. 

Avalere Health is committed to helping manufacturers and other healthcare stakeholders develop the evidence generation and market access strategies needed to reach EVERY PATIENT POSSIBLE. ISPOR is a great opportunity to connect with Avalere Health experts who can support you in: 

 

Using RWE to advance commercial business success 

• Developing integrated evidence plans that align with access and are responsive to healthcare policy dynamics and evolving payer/HTA evidence expectations 

• Leveraging Delphi panels and structured expert elicitation to generate early consensus on evidence needs, treatment pathways, and decision-maker expectations 

• Supporting manufacturers in navigating a dynamic commercialization environment through curated RWE that articulates asset value to position product for success in long-term and post-launch and informs access, value messaging, and lifecycle strategy 

• Assessing patient heterogeneity in the real world to optimize patient identification of high-risk groups, subgroups responding to treatment, and those with barriers to care using advanced analytics and segmentation approaches 

 

Improving clinical development and evidence generation strategies to support drug pricing in a post-IRA landscape where foreign reference pricing and tariffs are possible:  

• Advising on early decision making in clinical development cycles given substantial investment in clinical trials with explicit consideration of IRA timelines, negotiation risk, and pricing durability 

• Providing unique insights into investment decisions, clinical development programs, and product lifecycle planning in both US and global markets including MFN / international reference pricing exposure and cross-market implications 

• Supporting clients in maximizing evidence applicability and value strategies in response to new policy realities (e.g., IRA Part D Redesign and Negotiation, prescription drug affordability boards, Joint Clinical Assessments) and informing value-based contracting and net price optimization strategies 

• Designing evidence generation strategies that anticipate future access constraints, including state-level affordability actions and evolving payer management.   

 

Building a patient-centric value story to move the needle with healthcare decision makers  

• Improving access by creating patient-centric value stories in a way that is relevant to decision makers and grounded in real-world outcomes and system-level impact 

• Navigating methodological challenges in patient-centered data collection to support manufacturers in real-world treatment settings including integration of digital health tools, ePROs, and remote monitoring 

• Quantifying the direct and indirect burden patients face and developing patient-centered frameworks inclusive of caregiver burden, SDOH, and health equity considerations 

• Incorporating patient preference evidence and applying implementation science to demonstrate real-world effectiveness and inform decision-making 

 

We are also pleased to share recent research findings in three areas. Stop by the poster and exhibit hall to see: 

• Association Between Emergency Department–Involved Cancer Diagnosis and Post-Diagnosis Healthcare Expenditures in a National SEER-Medicare Cohort   

• Beyond “Cured”: Preferred Terminology, Milestones, and Evidence for Payer Decision-Making in Early-Stage Melanoma  

• Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus abemaciclib plus ET in the adjuvant treatment of HR+/HER2− early breast cancer (EBC) at high risk of recurrence: a Canadian payer perspective  

• Defining Curative Potential in Early-Stage Melanoma: Where Physicians and Payers Align and Where They Don’t